Blog Hakkında Generi Biotech Launches Precision BCRABL1 Test for Blood Cancer Diagnosis

For patients battling blood cancers, a precise genetic test can mean the difference between uncertainty and targeted treatment. The BCR-ABL1 fusion gene serves as both a diagnostic cornerstone and critical prognostic marker for hematologic malignancies. Now, Generi Biotech has introduced a revolutionary real-time PCR test kit called "gb ONCO BCR-ABL DETECT" that promises to transform detection capabilities.

Traditional BCR-ABL1 tests often focus on common fusion types, potentially missing rare but clinically significant variants. The new single-step RT-qPCR technology in this kit qualitatively identifies multiple BCR-ABL1 fusion variants simultaneously, including uncommon patterns. This comprehensive approach ensures clinicians receive complete genetic profiles, preventing treatment delays caused by undetected mutations.

The kit's breakthrough lies in its integrated single-tube design that combines reverse transcription and PCR amplification. This streamlined process reduces handling time, minimizes contamination risks, and maintains exceptional accuracy. Fluorescent probe technology specifically identifies different fusion variants, while built-in quality controls—including monitoring of the GUSB reference gene—guarantee reliable results for clinical decision-making.

While best known for its role in chronic myeloid leukemia (CML), the BCR-ABL1 fusion gene also drives other hematologic cancers like acute lymphoblastic leukemia (ALL). The test supports diagnosis, prognosis assessment, and personalized treatment planning across these conditions. For post-transplant patients, it enables sensitive monitoring for early relapse detection.

The kit employs four fluorescent channels to capture diverse mutations:

• FAM channel: Detects e14a2 variants
• HEX/JOE/VIC channel: Identifies e1a2 and e1a3 variants
• ROX channel: Monitors GUSB reference gene
• Cy5 channel: Captures e19a2 and e19a3 variants

Additional variants (e13a2, e14a3, e13a3, e6a2) are also detectable. This multiplex approach ensures high sensitivity and specificity for complex genetic profiles.

Meeting stringent EU IVD standards, the 48-reaction kit undergoes rigorous validation for performance, safety, and reliability. Laboratories worldwide can implement this standardized solution with confidence in its clinical validity.

Validated for major PCR platforms including Bio-Rad CFX systems, Applied Biosystems QuantStudio 5, and Corbett Research RG 3000, the kit facilitates workflow integration. Comprehensive technical documentation supports implementation.

Generi Biotech continues to innovate in genetic testing, offering companion products like gb HEMO PAI1 (4G/5G) and gb ONCO BRAF (V600E) kits alongside its gb OneStep RT-qPCR system. Ongoing research explores alternative fluorescent dyes to enhance cost-efficiency without compromising accuracy.

This diagnostic advancement represents a significant step toward precision hematology, enabling tailored therapies that may improve patient outcomes and quality of life. As genetic technologies evolve, such innovations promise to redefine cancer management paradigms.